OCC 2.63% 39.0¢ orthocell limited

Media thread, page-154

  1. 1,381 Posts.
    lightbulb Created with Sketch. 227
    Now, what big pharmaceutical is going to partner up and take Remplir into phase 3 trials in the US, we are so close yet so far, let’s hope towards the second half of the year or early next year

    Such a waste, where Remplir could be doing good, with thousand of patients losing out because of the approval process / commercialisation process taking so long, let’s try and fast track this process and get Remplir to market
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.